Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$62.0 million.

  • Regenxbio's Net Income towards Common Stockholders fell 392.14% to -$62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$178.1 million, marking a year-over-year increase of 2551.16%. This contributed to the annual value of -$227.1 million for FY2024, which is 1381.13% up from last year.
  • Per Regenxbio's latest filing, its Net Income towards Common Stockholders stood at -$62.0 million for Q3 2025, which was down 392.14% from -$70.9 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Net Income towards Common Stockholders ranged from a high of $294.0 million in Q4 2021 and a low of -$76.7 million during Q1 2022
  • Its 5-year average for Net Income towards Common Stockholders is -$40.5 million, with a median of -$61.9 million in 2023.
  • Over the last 5 years, Regenxbio's Net Income towards Common Stockholders had its largest YoY gain of 73584.91% in 2021, and its largest YoY loss of 76437.27% in 2021.
  • Quarter analysis of 5 years shows Regenxbio's Net Income towards Common Stockholders stood at $294.0 million in 2021, then tumbled by 120.38% to -$59.9 million in 2022, then fell by 5.18% to -$63.0 million in 2023, then rose by 18.67% to -$51.3 million in 2024, then decreased by 20.85% to -$62.0 million in 2025.
  • Its last three reported values are -$62.0 million in Q3 2025, -$70.9 million for Q2 2025, and $6.1 million during Q1 2025.